Conference Presentation, Panel, Fireside Chat
Health Care of the Future | Future of Health Summit 2024
- The elimination of cancer is projected to generate $50 trillion for the U.S. economy, with over 50 percent of future economic growth expected to stem from advances in public health and medical research.
- ARPA-H plans to pursue technically risky projects beyond the capacity of other entities, operating with program managers limited to a three-year term to drive urgency and utilizing an attrition model to reduce initial teams of five or six down to one or two over a five-year program.
- ARPA-H aims to fund over 1,700 submissions across 45 states and 34 countries for the Sprint for Women's Health, anticipating that seven awardees will be new to government work, with $10 million winners receiving a two-year runway and ARPA-H facilitating regulatory and reimbursement processes.
- Cancer funding is planned to be focused for 24 months to achieve a doubling of the NIH budget, while institutions like the NIH must be adequately funded to sustain innovation.
- The 21st Century Cures Act is expected to spur faster cures and further biomedical innovation, with a Cures 2.1 white paper planned for release before the end of the year to continue efforts into the next Congress after Congressman Bouchon's retirement.
- Health care legislation is predicted to advance on a bipartisan basis regarding prescription drug affordability and telehealth access, with a goal to secure a new partner for Cures 2.1 in the upcoming Congress.
- The Made in America Act intends to repatriate companies and encourage domestic manufacturing through tax opportunity zones, alongside a specific goal to lower prescription drug costs and encourage better pricing from manufacturers.
- Medicare Advantage is described as a future engine for seniors, with a hope to rethink reimbursement policies and address narratives that current costs are too high, which the speaker fears undermines value-based care arrangements.
- ARPA-H is expected to address women's health gaps by introducing new business models for challenges like pain measurement and home diagnostics, while the broader health care system faces concerns regarding its inability to finance high-cost curative therapies.
- Predictions include patients accessing genome sequencing on a chip at retail locations like 7-Eleven within five years, as well as the eventual creation of islet cells to cure Type 1 diabetes, though uncertainty remains regarding payment models for these cures.
- Technical success rates are expected to change dramatically in phase three due to improved biological understanding, yet vaccine resistance poses a risk of regressing health outcomes by decades.
- The speaker anticipates future curative therapies will carry high costs and raises concerns about ensuring affordable access without a worldwide national emergency, calling for a new financing approach to democratize access.